Search

Your search keyword '"Haubrich R."' showing total 452 results

Search Constraints

Start Over You searched for: Author "Haubrich R." Remove constraint Author: "Haubrich R."
452 results on '"Haubrich R."'

Search Results

1. Differential Escape Patterns within the Dominant HLA-B*57:03-Restricted HIV Gag Epitope Reflect Distinct Clade-Specific Functional Constraints

3. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

4. Risk factors associated with 10% weight change in treatment-naïve and treatment-experienced people living with HIV initiating or switching to an NNRTI- or INSTI-based antiretroviral therapy in four large cohort studies

6. COVID-19 treatment and outcomes: trends over 20 months in 338,930 US hospital patients with COVID-19 and pneumonia

10. T

11. K

12. M

17. Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adult patients living with HIV-1 in routine clinical practice : 6-month results of the BICSTaR cohort

20. A phase 3b open-label pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in virologically suppressed HIV-1 infected adults harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)

21. First real-life data of tenofovir alafenamide (TAF)-based ART in adult HIV-1-infected patients enrolled in the French TARANIS cohort: results on the use of E/C/F/TAF (Genvoya (R))

22. A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)

23. J Int AIDS Soc

26. Zwerchfell

27. Krankheiten der Harnorgane

29. Erkrankungen des Zwerchfells

31. Krankheiten der Pleura

32. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study

33. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

34. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

35. Darstellung von Bewegungsvorgängen

38. Efficacy and safety of ledipasvir/sofosbuvir, with or without ribavirin, for treatment of hepatitis C virus-mono and HCV/HIV co-infected patients who have failed prior treatment with non-NS5A, SOF-based therapies

39. Impact of pre-adapted HIV transmission

46. Book Reviews

47. Differential escape patterns within the dominant HLA-B*57:03-restricted HIV gag epitope reflect distinct Clade-Specific functional constraints

48. Loss of Circulating CD4 T Cells with B Cell Helper Function during Chronic HIV Infection

49. Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy

50. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro

Catalog

Books, media, physical & digital resources